Adrienne Monson – Lifestyle
Author:
Teva Pharmaceutical Industries Ltd
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
April 29, 2026
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
April 15, 2026
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
April 14, 2026
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
March 30, 2026
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
March 19, 2026
Teva Releases Q1 2026 Aide Memoire
March 19, 2026